Insights in Anaphylaxis and Clonal Mast Cell Disorders

The prevalence of anaphylaxis among patients with clonal mast cell disorders (MCD) is clearly higher comparing to the general population. Due to a lower frequency of symptoms outside of acute episodes, clonal MCD in the absence of skin lesions might sometimes be difficult to identify which may lead...

Full description

Bibliographic Details
Main Authors: David González-de-Olano, Iván Álvarez-Twose
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-07-01
Series:Frontiers in Immunology
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fimmu.2017.00792/full
id doaj-b638d9fd6f9f4b0090ad6ccc88827b6c
record_format Article
spelling doaj-b638d9fd6f9f4b0090ad6ccc88827b6c2020-11-24T21:00:24ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-07-01810.3389/fimmu.2017.00792269158Insights in Anaphylaxis and Clonal Mast Cell DisordersDavid González-de-Olano0Iván Álvarez-Twose1Allergy Department, Hospital Universitario Ramón y Cajal, Madrid, SpainInstituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, SpainThe prevalence of anaphylaxis among patients with clonal mast cell disorders (MCD) is clearly higher comparing to the general population. Due to a lower frequency of symptoms outside of acute episodes, clonal MCD in the absence of skin lesions might sometimes be difficult to identify which may lead to underdiagnosis, and anaphylaxis is commonly the presenting symptom in these patients. Although the release of mast cell (MC) mediators upon MC activation might present with a wide variety of symptoms, particular clinical features typically characterize MC mediator release episodes in patients with clonal MCD without skin involvement. Final diagnosis requires a bone marrow study, and it is recommended that this should be done in reference centers. In this article, we address the main triggers for anaphylaxis, risk factors, clinical presentation, diagnosis, and management of patients with MC activation syndromes (MCASs), with special emphasis on clonal MCAS [systemic mastocytosis and mono(clonal) MC activations syndromes].http://journal.frontiersin.org/article/10.3389/fimmu.2017.00792/fullanaphylaxisclonalmast cellmast cell activation syndromemastocytosis
collection DOAJ
language English
format Article
sources DOAJ
author David González-de-Olano
Iván Álvarez-Twose
spellingShingle David González-de-Olano
Iván Álvarez-Twose
Insights in Anaphylaxis and Clonal Mast Cell Disorders
Frontiers in Immunology
anaphylaxis
clonal
mast cell
mast cell activation syndrome
mastocytosis
author_facet David González-de-Olano
Iván Álvarez-Twose
author_sort David González-de-Olano
title Insights in Anaphylaxis and Clonal Mast Cell Disorders
title_short Insights in Anaphylaxis and Clonal Mast Cell Disorders
title_full Insights in Anaphylaxis and Clonal Mast Cell Disorders
title_fullStr Insights in Anaphylaxis and Clonal Mast Cell Disorders
title_full_unstemmed Insights in Anaphylaxis and Clonal Mast Cell Disorders
title_sort insights in anaphylaxis and clonal mast cell disorders
publisher Frontiers Media S.A.
series Frontiers in Immunology
issn 1664-3224
publishDate 2017-07-01
description The prevalence of anaphylaxis among patients with clonal mast cell disorders (MCD) is clearly higher comparing to the general population. Due to a lower frequency of symptoms outside of acute episodes, clonal MCD in the absence of skin lesions might sometimes be difficult to identify which may lead to underdiagnosis, and anaphylaxis is commonly the presenting symptom in these patients. Although the release of mast cell (MC) mediators upon MC activation might present with a wide variety of symptoms, particular clinical features typically characterize MC mediator release episodes in patients with clonal MCD without skin involvement. Final diagnosis requires a bone marrow study, and it is recommended that this should be done in reference centers. In this article, we address the main triggers for anaphylaxis, risk factors, clinical presentation, diagnosis, and management of patients with MC activation syndromes (MCASs), with special emphasis on clonal MCAS [systemic mastocytosis and mono(clonal) MC activations syndromes].
topic anaphylaxis
clonal
mast cell
mast cell activation syndrome
mastocytosis
url http://journal.frontiersin.org/article/10.3389/fimmu.2017.00792/full
work_keys_str_mv AT davidgonzalezdeolano insightsinanaphylaxisandclonalmastcelldisorders
AT ivanalvareztwose insightsinanaphylaxisandclonalmastcelldisorders
_version_ 1716779784900444160